A new contained human immunodeficiency virus type 1 host cell system for evaluation of antiviral activities of interferons and other agents in vitro

Antiviral Research

Volumn 42, Issue 3, 1999, Pages 177-187

  Moussazadeh, Mitra ^a   Hua, Ji ^a   Sidhu, Maninder K ^a   Zhao, Xiao Xia ^a   Fitzgibbon, Joseph E ^b   Liao, Mei June ^a   Rashidbaigi, Abbas ^a  

^a Interferon Sciences Inc   (United States)

^b Department of Emergency Medicine   (United States)

Author keywords

Antiviral; Epithelial cells; HIV; IFN

Indexed keywords

ALPHAN3 INTERFERON; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIBIOTIC G 418; ANTIVIRUS AGENT; INTERFERON; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CONFERENCE PAPER; DRUG SENSITIVITY; HELA CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; PRIORITY JOURNAL;

ANTI-HIV AGENTS; ANTIGENS, CD4; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION; GENE PRODUCTS, REV; GENE PRODUCTS, TAT; HELA CELLS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INTERFERON-ALPHA; NELFINAVIR; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; SAQUINAVIR; ZIDOVUDINE;

EID: 0032785672     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(99)00014-5     Document Type: Conference Paper

References (30)

1. Blauvelt A., Asada H., Saville M.W., Klaus-Kovtun V., Altman D.J., Yarchoan R., Katz S.I. Productive infection of dendritic cells by HIV-1 and their ability to capture virus are mediated through separate pathways, J. Clin. Invest. 100:1997;2043-2053.
2. Brand, D., Beal, J., Plasse, T., Trout, J.R., Fedorczyk, D., 1998. Alferon HIV Study Group. Natural interferon alpha (IFN) treatment of HIV patients (pts): a randomized, placebo-controlled, double-blinded study. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy abstracts manual, p. 393.
3. Chen H., Boyle T.J., Malim M.H., Cullen B.R., Lyerly H.K. Derivation of a biologically contained replication system for human immunodeficiency virus type 1, Proc. Natl. Acad. Sci. USA. 89:1992;7678-7682.
4. Colon C.P., Kenerman P., Edwards A., Larder B.A., Phillips R.E. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance., J. Infect. Dis. 169:1994;411-415.
5. Erice A., Mayers D.L., Strike D.G., Sannerud K.J., McCutchan F.E., Henry K., Balfour H.H. Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1, New Engl. J. Med. 328:1993;1163-1165.
6. Felgner P.L., Gadek T.R., Holm M., Roman R., Chan H.W., Wenz M., Northrop J.P., Ringold G.M., Danielsen M. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure, Proc. Natl. Acad. Sci. USA. 84:1987;7413-7417.
7. Fernie B.F., Poli G., Fauci A.S. Alpha interferon suppresses virion but not soluble human immunodeficiency virus antigen production in chronically infected T-lymphocytic cells, J. Virol. 65:1991;3968-3971.
8. Fitzgibbon J.E., Howell R.M., Haberzettl C.A., Sperber S.J., Gocke D.J., Dubin D.T. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′, 3′-dideoxycytidine. Antimicrob. Agents Chemother. 36:1992;153-157.
9. Gautier C., Mehtali M., Lathe R. A ubiquitous mammalian expression vector, pHMG, based on a housekeeping gene promoter. Nucl. Acids Res. 17:1989;8389.
10. Goldman L.A., Cutrone E.C., Kotenko S.V., Krause C.D., Langer J.A. Modification of vectors pEF-BOS, pcDNA1 and pcDNA3 result in improved convenience and expression. Biotechniques. 21:1996;1013-1015.
11. Hecht F.M., Grant R.M., Petropoulos C.J., Dilion B., Chesney M., Tian H., Hellman N.S., Bandrapalli N.I., DiGilio L., Branson B., Kahn J.O. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors, New Engl. J. Med. 339:1998;307-311.
12. Imrie A., Beveridge A., Genn W., Vizzard J., Cooper D.A. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study group, J. Infect. Dis. 175:1997;1502-1506.
13. Johnson, V.A., Byington, R.E., 1990. Techniques in HIV Research, Aldovini and Walker, pp. 71-76.
14. Kemp S.D., Shi C., Bloor S., Harrigan P.R., Mellors J.W., Larder B.A. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2′,3′-dideoxy-3′-thiacytidine, J. Virol. 72:1998;5093-5098.
15. Kent S.J., Woodward A., Zhao A. Human immunodeficiency virus type 1 (HIV-1)-specific T cell responses correlate with control of acute HIV-1 infection in macaques, J. Infect. Dis. 176:1997;1188-1197.
16. Lane H.C. Interferons in HIV and related diseases. AIDS Suppl. 3:1994;S19-S23.
17. Mahy, B.W.J. (ed.), 1985. Virology a Practical Approach. IRL Press, Washington, DC.
18. Maddon P.J., Littman D.R., Godfrey M., Maddon D.E., Chess L., Axel R. The isolation and nucleotide sequence of a cDNA encoding the T cell surface protein T4: a new member of the immunoglobulin gene family. Cell. 42:1985;93-104.
19. Maddon P.J., Dalgleish A.G., McDougal J.S., Clapham P.R., Weiss R.A., Axel R. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell. 47:1986;333-348.
20. McCallus D.E., Ugen K.E., Sato A.I., Williams W.V., Weiner D.B. Construction of a recombinant bacterial human CD4 expression system producing a bioactive CD4 molecule. Viral Immunol. 5:1992;163-172.
21. Oravecz T., Norcross M.A. Costimulatory properties of the human CD4 molecule: enhancement of CD3-induced T cell activation by human immunodeficiency virus type 1 through viral envelope glycoprotein gp120, AIDS Res. Hum. Retroviruses. 9:1993;945-955.
22. Poiesz B.J., Ruscetti F.W., Gazdar A.F., Bunn P.A., Minna J.D., Gallo R.C. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma, Proc. Natl. Acad. Sci. USA. 77:1980;7415-7419.
23. Popovic M., Sarngadharan M.G., Read E., Gallo R.C. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science. 224:1984;497-500.
24. Ralph S.J., Wines B.D., Payne M.J., Grubb D., Hatzinisiriou I., Linnane A.W., Devenish R.J. Resistance of melanoma cell lines to interferons correlates with reduction of IFN-induced tyrosine phosphorylation, J. Immunol. 154:1995;2248-2256.
25. Sambrook, J., Fritsch, E.F., Maniatis, T. (eds.) (1989) Molecular Cloning: a Laboratory Approach (2nd ed.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
26. Schwartz D.H., Castillo R.C., Arango-Jaramillo S., Sharma U.K., Song H.F., Sridharan G. Chemokine-independent in vitro resistance to human immunodeficiency virus (HIV-1) correlating with low viremia in long-term and recently infected HIV-1-positive persons, J. Infect. Dis. 176:1997;1168-1174.
27. Skillman D.R., Malone J.L., Decker C.F., Wagner K.F., Mapou R.L., Liao M.J., Testa D., Meltzer M.S. Phase I trial of interferon alfa-n3 in early-stage human immunodeficiency virus type 1 disease: evidence for drug safety, tolerance, and antiviral activity, J. Infect. Dis. 173:1996;1107-1114.
28. Southern P.J., Berg P. Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter, J. Mol. Appl. Genet. 1:1982;327-341.
29. Wigler M., Silverstein S., Lee L.S., Pellicer A., Cheng Y.-C., Axel R. Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells. Cell. 11:1977;223-232.
30. Wysocki L.J., Sato V.L. 'Panning' for lymphocytes: a method for cell selection, Proc. Natl. Acad. Sci. USA. 75:1978;2844-2848.